NVAX
Price
$7.56
Change
+$0.09 (+1.20%)
Updated
Sep 2, 04:59 PM (EDT)
Capitalization
1.21B
64 days until earnings call
XNCR
Price
$8.54
Change
+$0.41 (+5.04%)
Updated
Sep 2, 04:59 PM (EDT)
Capitalization
579.86M
69 days until earnings call
Interact to see
Advertisement

NVAX vs XNCR

Header iconNVAX vs XNCR Comparison
Open Charts NVAX vs XNCRBanner chart's image
Novavax
Price$7.56
Change+$0.09 (+1.20%)
Volume$82.76K
Capitalization1.21B
Xencor
Price$8.54
Change+$0.41 (+5.04%)
Volume$16.71K
Capitalization579.86M
NVAX vs XNCR Comparison Chart in %
Loading...
NVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XNCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NVAX vs. XNCR commentary
Sep 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NVAX is a Buy and XNCR is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 03, 2025
Stock price -- (NVAX: $7.47 vs. XNCR: $8.13)
Brand notoriety: NVAX: Notable vs. XNCR: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NVAX: 93% vs. XNCR: 111%
Market capitalization -- NVAX: $1.21B vs. XNCR: $579.86M
NVAX [@Biotechnology] is valued at $1.21B. XNCR’s [@Biotechnology] market capitalization is $579.86M. The market cap for tickers in the [@Biotechnology] industry ranges from $100.25B to $0. The average market capitalization across the [@Biotechnology] industry is $1.85B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NVAX’s FA Score shows that 1 FA rating(s) are green whileXNCR’s FA Score has 1 green FA rating(s).

  • NVAX’s FA Score: 1 green, 4 red.
  • XNCR’s FA Score: 1 green, 4 red.
According to our system of comparison, both NVAX and XNCR are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NVAX’s TA Score shows that 4 TA indicator(s) are bullish while XNCR’s TA Score has 5 bullish TA indicator(s).

  • NVAX’s TA Score: 4 bullish, 5 bearish.
  • XNCR’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, XNCR is a better buy in the short-term than NVAX.

Price Growth

NVAX (@Biotechnology) experienced а -4.72% price change this week, while XNCR (@Biotechnology) price change was -3.33% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.83%. For the same industry, the average monthly price growth was +22.37%, and the average quarterly price growth was +32.94%.

Reported Earning Dates

NVAX is expected to report earnings on Nov 05, 2025.

XNCR is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Biotechnology (+6.83% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NVAX($1.21B) has a higher market cap than XNCR($580M). NVAX YTD gains are higher at: -7.090 vs. XNCR (-64.621). NVAX has higher annual earnings (EBITDA): 496M vs. XNCR (-125.38M). NVAX has more cash in the bank: 612M vs. XNCR (444M). XNCR has less debt than NVAX: XNCR (67.9M) vs NVAX (228M). NVAX has higher revenues than XNCR: NVAX (1.08B) vs XNCR (147M).
NVAXXNCRNVAX / XNCR
Capitalization1.21B580M209%
EBITDA496M-125.38M-396%
Gain YTD-7.090-64.62111%
P/E Ratio3.36N/A-
Revenue1.08B147M734%
Total Cash612M444M138%
Total Debt228M67.9M336%
FUNDAMENTALS RATINGS
NVAX vs XNCR: Fundamental Ratings
NVAX
XNCR
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
81
Overvalued
76
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
6065
P/E GROWTH RATING
1..100
175
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XNCR's Valuation (76) in the Biotechnology industry is in the same range as NVAX (81). This means that XNCR’s stock grew similarly to NVAX’s over the last 12 months.

XNCR's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as NVAX (100). This means that XNCR’s stock grew similarly to NVAX’s over the last 12 months.

XNCR's SMR Rating (97) in the Biotechnology industry is in the same range as NVAX (100). This means that XNCR’s stock grew similarly to NVAX’s over the last 12 months.

NVAX's Price Growth Rating (60) in the Biotechnology industry is in the same range as XNCR (65). This means that NVAX’s stock grew similarly to XNCR’s over the last 12 months.

XNCR's P/E Growth Rating (5) in the Biotechnology industry is in the same range as NVAX (17). This means that XNCR’s stock grew similarly to NVAX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NVAXXNCR
RSI
ODDS (%)
Bearish Trend 5 days ago
90%
Bullish Trend 5 days ago
67%
Stochastic
ODDS (%)
Bullish Trend 5 days ago
85%
Bullish Trend 5 days ago
75%
Momentum
ODDS (%)
Bearish Trend 5 days ago
88%
Bullish Trend 5 days ago
69%
MACD
ODDS (%)
Bearish Trend 5 days ago
88%
Bullish Trend 5 days ago
75%
TrendWeek
ODDS (%)
Bearish Trend 5 days ago
89%
Bearish Trend 5 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 5 days ago
83%
Bearish Trend 5 days ago
85%
Advances
ODDS (%)
Bullish Trend 16 days ago
84%
Bullish Trend 5 days ago
71%
Declines
ODDS (%)
Bearish Trend 8 days ago
89%
Bearish Trend 8 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 5 days ago
79%
Aroon
ODDS (%)
Bullish Trend 5 days ago
85%
Bearish Trend 5 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
NVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XNCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
QUERX21.750.03
+0.14%
AQR Large Cap Defensive Style R6
SMUYX10.03N/A
N/A
SEI Multi-Strategy Alternative Y (SIMT)
DRGVX49.81-0.04
-0.08%
BNY Mellon Dynamic Value Fund I
FCLZX13.41-0.10
-0.74%
Fidelity Advisor Climate Action Z
CGJIX73.33-0.64
-0.87%
Calvert US Large Cap Growth Rspnb Idx I

NVAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVAX has been loosely correlated with MRNA. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if NVAX jumps, then MRNA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVAX
1D Price
Change %
NVAX100%
-1.45%
MRNA - NVAX
48%
Loosely correlated
-1.55%
BNTX - NVAX
43%
Loosely correlated
-1.89%
ARCT - NVAX
40%
Loosely correlated
-1.68%
XNCR - NVAX
37%
Loosely correlated
+0.99%
CRSP - NVAX
36%
Loosely correlated
-2.30%
More

XNCR and

Correlation & Price change

A.I.dvisor indicates that over the last year, XNCR has been loosely correlated with CRNX. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if XNCR jumps, then CRNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XNCR
1D Price
Change %
XNCR100%
+0.99%
CRNX - XNCR
62%
Loosely correlated
+1.11%
SYRE - XNCR
56%
Loosely correlated
-1.38%
BEAM - XNCR
55%
Loosely correlated
-2.91%
IDYA - XNCR
53%
Loosely correlated
-1.52%
CGON - XNCR
53%
Loosely correlated
+0.39%
More